Importantly, thiazolidinediones, PPAR-γ agonists currently used as therapeutic agents in T2D subjects, primarily act in the adipose tissue where PPAR-γ is predominantly expressed, promote lipid uptake and storage, and stimulate lipogenic activities in fat cells, thereby leading to an improvement in insulin resistance and a reduction in blood glucose levels [53,54]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.